AI brief of an SEC Form 8-K · DBV Technologies S.A. (DBVT)

DBV Technologies Q3 net loss nearly doubles to $64.5 million; going concern doubt flagged

Negative Impact 4 of 5 earnings Written later

DBV Technologies reported a third-quarter 2026 net loss of $64.5 million, up from $33.2 million a year earlier, as research, sales, and administrative spending rose ahead of a potential U.S. launch. The filing states that substantial doubt exists about the company's ability to continue as a going concern, and that its $165.7 million in cash funds operations only into the third quarter of 2027. Shareholders should note that the company says it will need additional capital, with availability and terms uncertain.

Key points

  • Q3 2026 net loss was $64.5 million versus $33.2 million in Q3 2025; net loss per share was $0.14 versus $0.24.
  • Cash and cash equivalents were $165.7 million as of September 30, 2026, which the company says funds operations into the third quarter of 2027.
  • The BLA for the VIASKIN Peanut Patch in children aged 4 through 7 was submitted on September 29, 2026, with Priority Review requested; FDA's filing decision is expected in Q4 2026.
  • The company refreshed its $150 million ATM program and reports a $50 million gross proceeds sale of ADSs to RA Capital Management.

The filing

CompanyDBV Technologies S.A. (DBVT)
Form8-K, current report
Filed with the SECOct 28, 2026, 5:24 PM ET
Accession number0001193125-26-436411

Items reported: 2.02 Results of Operations

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 8:38 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on October 28, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.